Real‐world data for lenalidomide maintenance in responding patients of diffuse large B‐cell lymphoma

Abstract Background Approximately 40% patients of diffuse large B‐cell lymphoma (DLBCL) would develop disease recurrence/progression after first‐line R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) induction therapy, with highly poor prognosis. An effective strategy to...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Xiaoyan Wang, Lu Yu, Xinlu Jiang, Kaiyang Ding
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2023-05-01
coleção:	Cancer Medicine
Assuntos:	diffuse large B‐cell lymphoma lenalidomide maintenance therapy R‐CHOP recurrence
Acesso em linha:	https://doi.org/10.1002/cam4.5790
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!